Chemical Research in Chinese Universities ›› 2015, Vol. 31 ›› Issue (2): 235-243.doi: 10.1007/s40242-015-4335-8

• Articles • Previous Articles     Next Articles

Design, Synthesis and Antitumor Activity of Novel Indolin-2-one Derivatives Containing 4-Thiazolidinone Moiety

LIU Zijian1, HOU Yunlei1, ZHANG Guogang2, XU Ning1, MI Bin1, GONG Ping1, ZHAO Yanfang1   

  1. 1. Key Laboratory of Structure-based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
    2. State Key Laboratory Breeding Base-Hebei Province Key Laboratory of Molecular Chemistry for Drug, College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, P. R. China
  • Received:2014-09-05 Revised:2015-01-04 Online:2015-04-01 Published:2015-01-19
  • Contact: ZHAO Yanfang E-mail:yanfangzhao@126.com
  • Supported by:

    Supported by the Program for Innovative Research Team of the Ministry of Education of China and the Program for Liaoning Innovative Research Team in University, China(No.IRT1073), and the National Natural Science Foundation of China (No.81202405)

Abstract:

A series of novel indolin-2-one derivatives containing 4-thiazolidinone moiety(7a―7r) were synthesized and evaluated for their in vitro antitumour activities against MDA-MB-231(human breast cancer), H460(human lung cancer) and HT-29(human colon cancer) cell lines by standard 3-(4,5-dimethylthiazae-2-yl)-2,5-diphenyltetrazo- lium bromide(MTT) assay. Representative compounds(7d, 7k, 7m, 7p) with higher cytotoxicity were further examined against one normal cell line(WI-38, human fetal lung fibroblasts). The preliminary investigation shows that most of the compounds display moderate to excellent potency and high selectivity against different human cancer cell lines. In particular, the most potent compound 7m shows promising cytotoxicity against MDA-MB-231, H460 and HT-29 cell lines with IC50 values of 0.78, 0.056 and 0.018 μmol/L, respectively. The potency is much higher than that of Sunitinib(IC50=3.46 μmol/L against MDA-MB-231, IC50=2.59 μmol/L against H460, IC50=1.50 μmol/L against HT-29) by 4.4, 46.3 and 83.3 fold.

Key words: Indolin-2-one, 4-Thiazolidinone, Antitumour activity